If you have an autoimmune disease, you may worry about more than joint pain or skin rashes. You might also worry about your heart. Many people with lupus or rheumatoid arthritis face a higher risk of heart attacks and strokes. This has puzzled doctors for years. Now, a new review suggests a clear reason why.
The review points to a shared inflammatory pathway that connects autoimmune disease and heart disease. It explains how the body’s own immune system can drive chronic damage in both places. This could change how doctors think about treatment in the future.
Autoimmune diseases happen when the immune system attacks the body’s own tissues. Lupus and rheumatoid arthritis are two common examples. They cause swelling, pain, and organ damage. Heart disease is also driven by inflammation, especially in the arteries. The new review shows these two problems may be more connected than we thought.
The link is a self-amplifying inflammatory loop. Think of it like a fire that keeps feeding itself. Once started, it burns hotter and spreads wider. This loop may explain why people with autoimmune disease have more plaque in their arteries and more heart events over time.
Here’s the twist. The review focuses on two processes that were once studied separately. One is called NETs, short for neutrophil extracellular traps. The other is called pyroptosis, a type of programmed cell death. Together, they form what the authors call the NET-pyroptosis axis.
To understand this, imagine a security guard who sets traps to catch intruders. Neutrophils are white blood cells that act like that guard. They release NETs, which are sticky webs of DNA and proteins, to trap germs. But in autoimmune disease, these traps can also damage healthy tissue.
Pyroptosis is different. It is a way cells die that triggers strong inflammation. When a cell undergoes pyroptosis, it bursts open and releases signals that call more immune cells to the area. This can be helpful during an infection. But in chronic disease, it can make inflammation worse.
The review shows these two processes feed each other. NETs can trigger pyroptosis in nearby cells. Pyroptosis can then cause more neutrophils to release NETs. This creates a loop that keeps inflammation high and tissue damage ongoing.
The study looked at recent research on lupus, rheumatoid arthritis, and heart disease. It synthesized findings from lab experiments and patient studies. The goal was to map out the signaling pathways that drive this loop and see how they affect disease progression.
One key player is a protein called Gasdermin D. It acts like a switch for pyroptosis. In some cases, it helps drive NET release. But the review notes it is not a universal executioner. Its role depends on the context and the type of cells involved.
Another protein, Gasdermin E, may be even more important. It helps immune cells talk to stromal cells, which are the support cells in tissues. This conversation can lead to structural damage, like bone erosion in joints or damage to the lining of blood vessels.
The review also highlights emerging treatments. One approach is to block an enzyme called peptidylarginine deiminase 4, or PAD4. This enzyme helps neutrophils release NETs. Blocking it may reduce NET-driven damage. Another approach is to block gasdermin pores, which could calm pyroptosis and lower inflammation.
This does not mean these treatments are available now.
Experts say this review offers a new way to understand the link between autoimmune disease and heart risk. It explains why inflammation in one part of the body can affect another. It also gives drug developers a clear target for future therapies.
For patients, this means more conversations with doctors about heart health. If you have lupus or rheumatoid arthritis, you may need regular heart checkups. It also means that future treatments could target both autoimmune symptoms and heart risk at the same time.
The review has some limits. It is a synthesis of existing studies, not a new experiment. Many of the findings come from lab models or small patient groups. More research is needed to confirm how this pathway works in larger, more diverse populations.
Looking ahead, researchers plan to test drugs that block NETs or pyroptosis in clinical trials. If successful, these treatments could help reduce both autoimmune flares and heart disease risk. It may take years, but the path forward is clearer now than before.